- Check all risk factors present (Step 1 — Stage A criteria).
- Check any structural heart disease findings (Step 2 — Stage B criteria).
- Check any applicable symptom criteria (Step 3 — Stage C/D criteria).
- Optionally select the patient's NYHA functional class for cross-reference.
- The ACC/AHA HF stage and recommended action update automatically as you check items.
All computation runs in your browser; no values are stored or transmitted.
When to Use
The 2022 AHA/ACC/HFSA HF Guideline uses a 4-stage structural progression framework alongside the NYHA functional classification. Use this tool for initial and follow-up HF classification, guiding referral for advanced therapies, and communicating prognosis and GDMT targets.
Appropriate population
Adults being evaluated for heart failure risk, suspected pre-HF structural disease, symptomatic HF, or advanced HF. Particularly relevant for CKD patients: cardiorenal syndrome is common, and HF and CKD worsen each other. Use at initial presentation and at each follow-up to track progression and guide GDMT intensity.
Important caveats
This is a structured clinical checklist — not a numerical score. Accurate staging requires echocardiography and biomarker data (BNP/NT-proBNP). Stage assignment should integrate full clinical assessment including physical examination, imaging, and laboratory findings. This tool is for educational reference only.
Pearls & Pitfalls
Key clinical pearls
- Stage A does NOT mean the patient has HF — it means they are at risk.
- Stage progression is generally unidirectional (A→B→C→D); optimal treatment slows or prevents advancement.
- CKD is a Stage A risk factor AND worsens prognosis in Stage C/D.
- SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalization in both HFrEF and HFpEF.
- In CKD + HFrEF: ACEi/ARB/ARNI, beta-blockers, MRA (with caution re: hyperkalemia), and SGLT2i are all recommended.
NYHA Functional Class cross-reference
- Class I: No symptoms with ordinary activity
- Class II: Mild symptoms with ordinary activity → Stage C
- Class III: Marked symptoms with less-than-ordinary activity → Stage C–D
- Class IV: Symptoms at rest → Stage D
Common pitfalls
(1) Conflating Stage A (at risk) with early HF — Stage A patients have no structural disease and no symptoms. (2) Underestimating Stage D — recurrent hospitalizations and refractory symptoms despite maximal GDMT define advanced HF requiring specialist evaluation. (3) Missing cardiorenal interactions — worsening eGFR in treated HF may reflect cardiorenal syndrome rather than medication toxicity.
Why Use It
The ACC/AHA staging system standardizes HF communication and guides therapy intensity — different stages warrant different interventions. Unlike the NYHA functional class (which reflects current symptoms and can fluctuate), the ACC/AHA stage captures structural disease progression and is intended to be a unidirectional ratchet: patients can move forward (A→B→C→D) but not backward. This makes it a useful framework for long-term management planning, patient counseling, and determining when to escalate to advanced therapies or specialist referral.
ACC/AHA Heart Failure Staging — A through D
Check all applicable criteria in each step. The stage and recommended action update automatically.
Step 1 — Risk Factors / At-Risk Criteria (Stage A)
Step 2 — Structural Heart Disease (Stage B — Pre-HF)
Step 3 — HF Symptoms (Stage C / D)
⚕ HF staging requires clinical judgment, echocardiography, and biomarker data. This tool is a structured checklist, not a substitute for a full cardiovascular assessment. For educational reference only. Reference: Heidenreich PA et al., JACC 2022.
Next Steps
Use the ACC/AHA HF stage to guide therapy intensity and referral decisions.
- For Stage A: aggressive risk-factor modification — BP <130/80, HbA1c <7%, weight loss if obese, cardiotoxin avoidance. SGLT2i if DM + high CV risk.
- For Stage B: initiate ACEi/ARB and beta-blockers if EF reduced; ICD evaluation if EF <35%. Cardiology follow-up. Prevent progression to Stage C.
- For Stage C: full GDMT — ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i. Device therapy if EF <35%. Dietary Na restriction, fluid management. Address cardiorenal interactions if CKD present.
- For Stage D: advanced HF team referral. LVAD evaluation, transplant workup, palliative care integration. Nephrology co-management if CKD present.
Evidence & References
ACC/AHA HF Staging Framework
| Stage | Definition | NYHA Equivalent |
|---|---|---|
| Stage A — At Risk | Risk factors present (HTN, DM, obesity, family hx, cardiotoxin exposure, CKD); NO structural disease; NO symptoms | None (not yet HF) |
| Stage B — Pre-HF | Structural heart disease (reduced EF, LVH, wall-motion abnormality, elevated filling pressures) OR elevated BNP/NT-proBNP; NO current or prior HF symptoms | Class I (no symptoms) |
| Stage C — Symptomatic HF | Current or prior symptoms of HF (dyspnea, fatigue, reduced exercise tolerance) in the setting of underlying structural heart disease. Majority of HF patients. | Class I–IV |
| Stage D — Advanced HF | Marked symptoms at rest or minimal exertion despite maximally tolerated GDMT. Recurrent hospitalizations, poor QoL. Candidates for advanced therapies (MCS, transplant, palliative care). | Class III–IV |
References
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368.
